Athersys' MultiStem Has Enormous Potential In Trauma Treatment

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Free Report Location: https://quantum-corp.com/equity-research

Athersys (ATHX) is an international regenerative medicine company focusing on therapeutics that have best-in-class potential in areas of high unmet medical needs, especially in the critical care space. In this report, we examine MultiStem and its potential to succeed in treating severe physical trauma, a great unmet medical need, and the leading cause of death of individuals under the age of 45, and the third-largest cause of death in the United States.

Available evidence indicates that Athersys’ proprietary cell type, the multipotent adult progenitor cell (MAPC), which are the cells that comprise MultiStem, have more potent biological activity than the mesenchymal stem cell (MSC), which are adult stem cells sometimes compared to MAPCs used in studies by various other biotechnology companies, although MSC cell properties can vary.

According to available research, MAPCs are also much more scalable than MSCs. With a potential best-in-class, immune-privileged, allogeneic stem cell technology able to be produced in large quantities from one single donor, Athersys has the potential to become a premier global regenerative medicine company and generate handsome returns for investors.

We believe Athersys’ potent MAPCs have the potential to succeed in critical care where other approaches have failed due to the cells’ ability to affect multiple biological pathways in a dynamic manner. Athersys’ lead programs are in treating ischemic stroke and acute respiratory distress syndrome (ARDS). However, these great unmet medical needs as well as the recent COVID-19 pandemic have overshadowed the company’s phase 2 trial in severe trauma that is getting started.

In our opinion, this program, while in the early stages, theoretically has the potential to become Athersys’ largest source of revenue. Therefore, it is worth a deeper look to try to determine if MultiStem will be a success in trauma treatment.

Trauma pathology is complex and sometimes involves somewhat paradoxical immune states, including initial hyperinflammation followed by immune exhaustion, suppression, and local inflammation. This can result in complications including impaired wound healing, infections, and chronic inflammation which worsens patients’ quality of life.

MultiStem, as opposed to prior approaches to modify the immune response, has the potential to modulate the immune system without leaving individuals susceptible to infections and other complications, which was observed in its phase 2 trial in ischemic stroke. The common link between ischemic stroke, ARDS, and trauma is the hyperinflammatory response and subsequent medical complications, and Quantum is optimistic for Athersys to succeed in trauma given data obtained from other critical care medicine trials of MultiStem.

Disclosure:
Quantum Media Group may seek to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. However, at this time of this publication, Quantum does not do business with Athersys, Inc. This report is not intended to provide personal investment advice. The opinions herein do not consider individual client circumstances, objectives, needs, or goals, and therefore are not recommendations of any securities, financial instruments, or investment strategies. The reader of this report must make its, his, or her own independent decisions regarding any securities or financial instruments mentioned herein.
Partners or employees of Quantum or its affiliates may have a financial interest in the securities of Athersys, Inc. Quantum attests that all of the views outlined in this research report accurately reflect our personal views about any and all of the securities and companies covered by this report.
This is not in any sense an offer or solicitation for the purchase or sale of a security or financial instrument. The statements herein have been taken from sources we believe to be reliable, but such statements are made without any representation as to accuracy or completeness or otherwise, except with respect to any disclosures relative to Quantum or its research analysts. Opinions expressed are our own unless otherwise stated and are subject to change without notice.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.